{"id":13257,"date":"2019-08-11T23:14:55","date_gmt":"2019-08-11T23:14:55","guid":{"rendered":"https:\/\/beyondtype2.org\/resources\/primer-vistazo-a-baqsimi-glucagon-nasal\/"},"modified":"2024-11-13T20:03:41","modified_gmt":"2024-11-13T20:03:41","slug":"primer-vistazo-a-baqsimi-glucagon-nasal","status":"publish","type":"resources","link":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/","title":{"rendered":"Primer Vistazo a BAQSIMI Glucagon Nasal"},"content":{"rendered":"<p><strong><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-56137 alignright\" style=\"padding-left: 15px;\" src=\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baq2.gif\" width=\"137\" height=\"303\"><\/strong><\/p>\n<p><strong><br>\n<\/strong><a href=\"https:\/\/beyondtype1.org\/es\/glucagon-nasal-baqsimi-aprobado-por-la-fda\/\">Lilly anunci&oacute; recientemente que BAQSIMI, el primer tratamiento de emergencia no inyectable para episodios severos de hipoglucemia, ahora est&aacute; disponible en las farmacias de EE. UU.<\/a><\/p>\n<p>Hoy en la Conferencia Anual de AADE, el CEO de Beyond Type 1 Thom Scher se reuni&oacute; con una de las ex presidentas de AADE , Deborah Hinnen, APN, de Colorado Springs y con Julie Settles, MSN, APRN y Directora M&eacute;dica para una demostraci&oacute;n en persona del dispositivo de glucagon nasal.<\/p>\n<p>Algunas de las preguntas importantes a las que se dio respuesta en &nbsp;entrevista incluyen:<\/p>\n<p><strong>P) &iquest;Es necesario inhalar BAQSIMI?<\/strong><\/p>\n<p>No , BAQSIMI se absorbe pasivamente en la nariz y se puede administrar a alguien que est&aacute; inconsciente.<\/p>\n<p><strong>P) &iquest;BAQSIMI funcionar&aacute; en alguien que tiene un resfriado?<\/strong><\/p>\n<p>S&iacute;, BAQSIMI no se ve afectado por un resfriado, congesti&oacute;n o tratamiento simult&aacute;neo con el aerosol nasal de Afrin.<\/p>\n<p><strong> P) &iquest;BAQSIMI funciona igual que el glucagon inyectado?<\/strong><\/p>\n<p>S&iacute;, BAQSIMI es el mismo qu&iacute;mico &ndash; glucag&oacute;n &ndash; administrado a trav&eacute;s de las fosas nasales.<\/p>\n<p><strong>P) &iquest;Existen diferentes dosis de BAQSIMI seg&uacute;n talla y edad?<\/strong><\/p>\n<p>Una dosis &uacute;nica de 3 mg de BAQSIMI funciona para todas las personas de 4 a&ntilde;os en adelante.<\/p>\n<h2>Mira aqu&iacute; la demostraci&oacute;n en vivo y la entrevista<\/h2>\n<p>&nbsp;<\/p>\n<p>[youtube id=&raquo;ZabDZebtpOc&raquo; height=&raquo;400&Prime; width=&raquo;225&Prime; align=&raquo;center&raquo;]<\/p>\n<p>&nbsp;<\/p>\n<hr>\n<p>Para m&aacute;s informaci&oacute;n sobre costo &nbsp;BAQSIMI y disponibilidad da, <a href=\"https:\/\/beyondtype1.org\/es\/glucagon-nasal-baqsimi-aprobado-por-la-fda\/\">CLICK AQU&Iacute;<\/a>.<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>Lilly anunci&oacute; recientemente que BAQSIMI, el primer tratamiento de emergencia no inyectable para episodios severos de hipoglucemia, ahora est&aacute; disponible en las farmacias de EE. UU. Hoy en la Conferencia Anual de AADE, el CEO de Beyond Type 1 Thom Scher se reuni&oacute; con una de las ex presidentas de AADE , Deborah Hinnen, APN, [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":13260,"comment_status":"open","ping_status":"open","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-13257","resources","type-resources","status-publish","has-post-thumbnail","hentry","diabetes-types-tipo-1"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Primer Vistazo a BAQSIMI Glucagon Nasal | Beyond Type 1<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Primer Vistazo a BAQSIMI Glucagon Nasal | Beyond Type 1\" \/>\n<meta property=\"og:description\" content=\"Lilly anunci&oacute; recientemente que BAQSIMI, el primer tratamiento de emergencia no inyectable para episodios severos de hipoglucemia, ahora est&aacute; disponible en las farmacias de EE. UU. Hoy en la Conferencia Anual de AADE, el CEO de Beyond Type 1 Thom Scher se reuni&oacute; con una de las ex presidentas de AADE , Deborah Hinnen, APN, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/\" \/>\n<meta property=\"og:site_name\" content=\"Beyond Type 1\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/beyondtype1\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-13T20:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"733\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BeyondType1\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/\",\"url\":\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/\",\"name\":\"Primer Vistazo a BAQSIMI Glucagon Nasal | Beyond Type 1\",\"isPartOf\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png\",\"datePublished\":\"2019-08-11T23:14:55+00:00\",\"dateModified\":\"2024-11-13T20:03:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#primaryimage\",\"url\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png\",\"contentUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png\",\"width\":2048,\"height\":733},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/beyondtype1.org\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Primer Vistazo a BAQSIMI Glucagon Nasal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#website\",\"url\":\"https:\/\/beyondtype1.org\/es\/\",\"name\":\"Beyond Type 1\",\"description\":\"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.\",\"publisher\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/beyondtype1.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#organization\",\"name\":\"Beyond Type 1\",\"url\":\"https:\/\/beyondtype1.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg\",\"contentUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg\",\"width\":56,\"height\":56,\"caption\":\"Beyond Type 1\"},\"image\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/beyondtype1\",\"https:\/\/x.com\/BeyondType1\",\"http:\/\/instagram.com\/BeyondType1\/\",\"https:\/\/www.youtube.com\/c\/BeyondType1\",\"https:\/\/www.tiktok.com\/@beyondtype1\",\"https:\/\/www.linkedin.com\/company\/beyond-type1\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Primer Vistazo a BAQSIMI Glucagon Nasal | Beyond Type 1","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/","og_locale":"es_ES","og_type":"article","og_title":"Primer Vistazo a BAQSIMI Glucagon Nasal | Beyond Type 1","og_description":"Lilly anunci&oacute; recientemente que BAQSIMI, el primer tratamiento de emergencia no inyectable para episodios severos de hipoglucemia, ahora est&aacute; disponible en las farmacias de EE. UU. Hoy en la Conferencia Anual de AADE, el CEO de Beyond Type 1 Thom Scher se reuni&oacute; con una de las ex presidentas de AADE , Deborah Hinnen, APN, [&hellip;]","og_url":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/","og_site_name":"Beyond Type 1","article_publisher":"https:\/\/www.facebook.com\/beyondtype1","article_modified_time":"2024-11-13T20:03:41+00:00","og_image":[{"width":2048,"height":733,"url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BeyondType1","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/","url":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/","name":"Primer Vistazo a BAQSIMI Glucagon Nasal | Beyond Type 1","isPartOf":{"@id":"https:\/\/beyondtype1.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#primaryimage"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#primaryimage"},"thumbnailUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png","datePublished":"2019-08-11T23:14:55+00:00","dateModified":"2024-11-13T20:03:41+00:00","breadcrumb":{"@id":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#primaryimage","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/Baqsimi_First_Look_Header.png","width":2048,"height":733},{"@type":"BreadcrumbList","@id":"https:\/\/beyondtype1.org\/es\/primer-vistazo-a-baqsimi-glucagon-nasal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beyondtype1.org\/es\/"},{"@type":"ListItem","position":2,"name":"Primer Vistazo a BAQSIMI Glucagon Nasal"}]},{"@type":"WebSite","@id":"https:\/\/beyondtype1.org\/es\/#website","url":"https:\/\/beyondtype1.org\/es\/","name":"Beyond Type 1","description":"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.","publisher":{"@id":"https:\/\/beyondtype1.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beyondtype1.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/beyondtype1.org\/es\/#organization","name":"Beyond Type 1","url":"https:\/\/beyondtype1.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","width":56,"height":56,"caption":"Beyond Type 1"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/beyondtype1","https:\/\/x.com\/BeyondType1","http:\/\/instagram.com\/BeyondType1\/","https:\/\/www.youtube.com\/c\/BeyondType1","https:\/\/www.tiktok.com\/@beyondtype1","https:\/\/www.linkedin.com\/company\/beyond-type1\/"]}]}},"_links":{"self":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/13257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/types\/resources"}],"author":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/comments?post=13257"}],"version-history":[{"count":0,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/13257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media\/13260"}],"wp:attachment":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media?parent=13257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}